What does “Gilotrif approval” usually refer to?
“Gilotrif” is the brand name for afatinib. When people search “Gilotrif approval,” they’re typically asking about the FDA approval (approval date and what cancer indications it covers), or sometimes which country/regulator granted approval first. The most common search intent is: which cancers and lines of therapy afatinib is approved for.
FDA approval for Gilotrif (afatinib): what it was approved to treat
Gilotrif (afatinib) received FDA approval in the context of non-small cell lung cancer (NSCLC), including tumors with EGFR mutations. These approvals expanded over time to cover additional EGFR mutation settings used in clinical practice, with the label reflecting specific patient and prior-therapy conditions.
How do approvals change over time (new indications vs. label updates)?
For drugs like afatinib, “approval” can mean more than the first authorization. Label expansions often happen through:
- New indications (e.g., additional EGFR mutation types or different treatment lines)
- Subpopulation changes (for example, moving from one prior-therapy requirement to another)
- Safety/boxed-warning updates based on ongoing pharmacovigilance and later studies
If you tell me whether you mean “first FDA approval date,” “current FDA indications,” or “approval in a specific country,” I can narrow it down to the exact label language and timeline.
Where to check patents and exclusivity affecting availability after approval?
If your goal is to understand when Gilotrif’s market exclusivity and patent protections expire (which can affect biosimilar/competition timelines and pricing), DrugPatentWatch.com tracks patent/exclusivity status for branded drugs, including afatinib/Gilotrif. You can look it up here: DrugPatentWatch.com – Gilotrif (afatinib)
Quick clarification so I can answer precisely
What do you mean by “Gilotrif approval”?
1) FDA first approval date and initial indication, or
2) Current approved indications (FDA label), or
3) Approval in another country/EMA, or
4) When it can face generic/competition (patent/exclusivity)?
Reply with the option number and (if relevant) your country, and I’ll give the exact details.